Fiera Capital Corp Takes $215,000 Position in Boston Scientific Co. (NYSE:BSX)

Fiera Capital Corp bought a new position in shares of Boston Scientific Co. (NYSE:BSXGet Rating) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,550 shares of the medical equipment provider’s stock, valued at approximately $215,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Costello Asset Management INC increased its position in Boston Scientific by 1.7% during the third quarter. Costello Asset Management INC now owns 102,206 shares of the medical equipment provider’s stock worth $3,970,000 after acquiring an additional 1,757 shares during the period. Strengthening Families & Communities LLC increased its position in Boston Scientific by 6.9% during the third quarter. Strengthening Families & Communities LLC now owns 9,067 shares of the medical equipment provider’s stock worth $351,000 after acquiring an additional 584 shares during the period. Larson Financial Group LLC increased its position in Boston Scientific by 3,451.8% during the third quarter. Larson Financial Group LLC now owns 43,723 shares of the medical equipment provider’s stock worth $1,693,000 after acquiring an additional 42,492 shares during the period. Gilbert & Cook Inc. increased its position in Boston Scientific by 2.6% during the third quarter. Gilbert & Cook Inc. now owns 11,246 shares of the medical equipment provider’s stock worth $472,000 after acquiring an additional 289 shares during the period. Finally, NBW Capital LLC increased its position in Boston Scientific by 3.9% during the third quarter. NBW Capital LLC now owns 139,064 shares of the medical equipment provider’s stock worth $5,386,000 after acquiring an additional 5,279 shares during the period. Institutional investors own 90.23% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several analyst reports. Raymond James boosted their price target on shares of Boston Scientific from $48.00 to $54.00 in a report on Thursday, December 8th. StockNews.com initiated coverage on shares of Boston Scientific in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Citigroup initiated coverage on shares of Boston Scientific in a report on Tuesday, December 20th. They issued a “buy” rating and a $54.00 price target on the stock. Morgan Stanley boosted their price target on shares of Boston Scientific from $50.00 to $56.00 and gave the company an “overweight” rating in a report on Friday, January 6th. Finally, Mizuho initiated coverage on shares of Boston Scientific in a report on Thursday, December 22nd. They issued a “neutral” rating and a $52.00 price target on the stock. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 125,827 shares of the company’s stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $41.97, for a total transaction of $5,280,959.19. Following the transaction, the chief executive officer now owns 1,767,665 shares in the company, valued at approximately $74,188,900.05. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Boston Scientific news, CEO Michael F. Mahoney sold 125,827 shares of the business’s stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $41.97, for a total transaction of $5,280,959.19. Following the completion of the sale, the chief executive officer now directly owns 1,767,665 shares of the company’s stock, valued at approximately $74,188,900.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Wendy Carruthers sold 1,678 shares of the business’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $42.60, for a total value of $71,482.80. Following the sale, the executive vice president now directly owns 94,913 shares of the company’s stock, valued at $4,043,293.80. The disclosure for this sale can be found here. Insiders have sold a total of 220,265 shares of company stock worth $9,561,634 in the last 90 days. Corporate insiders own 0.66% of the company’s stock.

Boston Scientific Stock Down 0.0 %

Shares of NYSE BSX opened at $45.84 on Wednesday. The firm’s 50-day simple moving average is $45.56 and its 200 day simple moving average is $42.39. The company has a market cap of $65.66 billion, a price-to-earnings ratio of 109.15, a price-to-earnings-growth ratio of 2.30 and a beta of 0.83. The company has a quick ratio of 0.95, a current ratio of 1.45 and a debt-to-equity ratio of 0.49. Boston Scientific Co. has a 12-month low of $34.98 and a 12-month high of $47.95.

Boston Scientific (NYSE:BSXGet Rating) last issued its quarterly earnings results on Wednesday, October 26th. The medical equipment provider reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.44 by ($0.01). The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Boston Scientific had a return on equity of 14.55% and a net margin of 5.19%. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. During the same quarter last year, the company earned $0.41 EPS. On average, research analysts expect that Boston Scientific Co. will post 1.73 earnings per share for the current fiscal year.

Boston Scientific Profile

(Get Rating)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

Further Reading

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXGet Rating).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.